The effects of L-dihydroxyphenylalanine on alertness and mood in alpha-methyl-para-tyrosine-treated healthy humans. Further evidence for the role of catecholamines in arousal and anxiety
- PMID:8526970
- DOI: 10.1016/0893-133X(94)00134-L
The effects of L-dihydroxyphenylalanine on alertness and mood in alpha-methyl-para-tyrosine-treated healthy humans. Further evidence for the role of catecholamines in arousal and anxiety
Abstract
Treatment with alpha-methyl-para-tyrosine (AMPT), a catecholamine synthesis inhibitor, has been shown to produce pronounced increases in sleepiness and mild increases in negative mood and anxiety when administered to healthy male adults. The present study was conducted to ascertain whether these effects of AMPT are secondary to decreases in brain catecholamines or whether they represent nonspecific drug effects. Forty-one healthy males were randomized to one of four treatment groups. (1) Treatment with AMPT alone (AMPT/placebo); (2) treatment with AMPT plus L-dopa/carbidopa (AMPT plus L-dopa/carbidopa); (3) treatment with L-dopa/carbidopa alone (placebo plus L-dopa/carbidopa); or (4) treatment with placebo alone (placebo plus placebo). Repeated measures of alertness, mood, and anxiety were obtained over a three-day period of drug treatment and following drug discontinuation. As before, AMPT treatment led to increased sleepines. In addition, AMPT treatment led to decreased calmness, increased tension and anger, and a trend for increased depression. Replacement of catecholamine stores with L-dopa reversed the effects of AMPT and was associated with a more rapid recovery from AMPT's effects. These findings indicate that AMPT's effects on alertness and anxiety are catecholamine-specific. Further, they provide additional evidence that catecholamines are involved in the regulation of normal states of arousal, and they are consistent with the view that brain catecholaminergic dysregulation is involved in pathological anxiety states.
Similar articles
- Effects of catecholamine depletion on alertness and mood in rested and sleep deprived normal volunteers.McCann UD, Penetar DM, Shaham Y, Thorne DR, Sing HC, Thomas ML, Gillin JC, Belenky G.McCann UD, et al.Neuropsychopharmacology. 1993 Jun;8(4):345-56. doi: 10.1038/npp.1993.34.Neuropsychopharmacology. 1993.PMID:8099791Clinical Trial.
- The impact of gender on alpha-methyl-para-tyrosine mediated changes in prolactin secretion and 6-hydroxymelatonin sulfate excretion.Zimmermann RC, Krahn L, Klee G, Lu PY, Ory SJ, Lin SC.Zimmermann RC, et al.Psychoneuroendocrinology. 1996 Jul;21(5):469-78. doi: 10.1016/0306-4530(95)00049-6.Psychoneuroendocrinology. 1996.PMID:8888369Clinical Trial.
- Effects of alpha-methyl-para-tyrosine (AMPT) in drug-free depressed patients.Miller HL, Delgado PL, Salomon RM, Heninger GR, Charney DS.Miller HL, et al.Neuropsychopharmacology. 1996 Mar;14(3):151-7. doi: 10.1016/0893-133X(95)00072-L.Neuropsychopharmacology. 1996.PMID:8866698Clinical Trial.
- Endogenous catecholamines suppress thyrotropin secretion during the early follicular phase of the menstrual cycle.Plosker SM, Rabinovici J, Montalvo M, Jaffe RB.Plosker SM, et al.J Clin Endocrinol Metab. 1995 Aug;80(8):2530-3. doi: 10.1210/jcem.80.8.7629255.J Clin Endocrinol Metab. 1995.PMID:7629255
- alpha-Methyl-p-tyrosine: a review of its pharmacology and clinical use.Brogden RN, Heel RC, Speight TM, Avery GS.Brogden RN, et al.Drugs. 1981 Feb;21(2):81-9. doi: 10.2165/00003495-198121020-00001.Drugs. 1981.PMID:7009139Review.
Cited by
- Historical and Modern Evidence for the Role of Reward Circuitry in Emergence.Heshmati M, Bruchas MR.Heshmati M, et al.Anesthesiology. 2022 Jun 1;136(6):997-1014. doi: 10.1097/ALN.0000000000004148.Anesthesiology. 2022.PMID:35362070Free PMC article.Review.
- Response to pentagastrin after acute phenylalanine and tyrosine depletion in healthy men: a pilot study.Coupland N, Zedkova L, Sanghera G, Leyton M, Le Mellédo JM.Coupland N, et al.J Psychiatry Neurosci. 2001 May;26(3):247-51.J Psychiatry Neurosci. 2001.PMID:11394194Free PMC article.Clinical Trial.
- Dopamine-related deficit in reward learning after catecholamine depletion in unmedicated, remitted subjects with bulimia nervosa.Grob S, Pizzagalli DA, Dutra SJ, Stern J, Mörgeli H, Milos G, Schnyder U, Hasler G.Grob S, et al.Neuropsychopharmacology. 2012 Jul;37(8):1945-52. doi: 10.1038/npp.2012.41. Epub 2012 Apr 11.Neuropsychopharmacology. 2012.PMID:22491353Free PMC article.Clinical Trial.
- Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression.Bremner JD, Vythilingam M, Ng CK, Vermetten E, Nazeer A, Oren DA, Berman RM, Charney DS.Bremner JD, et al.JAMA. 2003 Jun 18;289(23):3125-34. doi: 10.1001/jama.289.23.3125.JAMA. 2003.PMID:12813118Free PMC article.Clinical Trial.
- Catecholamine depletion in first-degree relatives of individuals with mood disorders: An [(18)F]fluorodeoxyglucose positron emission tomography study.Savitz J, Nugent AC, Bellgowan PS, Wright N, Tinsley R, Zarate CA Jr, Herscovitch P, Drevets WC.Savitz J, et al.Neuroimage Clin. 2013 Mar 5;2:341-55. doi: 10.1016/j.nicl.2013.02.004. eCollection 2013.Neuroimage Clin. 2013.PMID:24179788Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Research Materials